Thus, the glucocorticoid receptor is a double-edged sword in prostate cancer. Due to it promoting the development of drug resistance in prostate cancer, it was shown to have oncogenic effects.

Thus, the glucocorticoid receptor is a double-edged sword in prostate cancer. Due to it promoting the development of drug resistance in prostate cancer, it was shown to have oncogenic effects.

Abbvie Inc. recently disclosed the discovery and structure of the anti-tumor necrosis factor (TNF) glucocorticoid receptor modulator (GRM) immunology antibody-drug conjugate (iADC) ABBV-154. The drug ...

Background: BMS-986156 is a fully human IgG1 agonist mAb that binds GITR and promotes T effector cell activation and possible reduction/inactivation of T regulatory cells. Preclinical data show ...